جست‌وجوی استاد و پژوهشگر

Hai-Quan Maoمشاهده پروفایل

استاد

• Biomaterials
• Regenerative Engineering
• Therapeutic Delivery
• +۳ مورد دیگر

Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.

Li Tangمشاهده پروفایل

دانشیار

• Immunoengineering
• Cancer Immunotherapy
• Immune Metabolism
• +۷ مورد دیگر

Li Tang is an Associate Professor with tenure at École polytechnique fédérale de Lausanne (EPFL), affiliated with the Institute of Bioengineering (IBI) and the Institute of Materials Science and Engineering (IMX) within the School of Engineering (STI). She leads the Laboratory of Biomaterials for Immunoengineering, focusing on developing innovative strategies at the intersection of immunology, materials science, and cancer therapy. Her work bridges fundamental research and clinical translation, with multiple ongoing clinical trials based on CAR-T cell therapies developed in her lab. B.S. in Chemistry, Peking University (2003–2007) Ph.D. in Materials Science and Engineering, University of Illinois at Urbana-Champaign (2007–2012) Postdoctoral Fellow, MIT (2013–2016) Her research lies at the forefront of immunoengineering, integrating chemical, metabolic, and mechanical approaches to modulate immune responses. Key areas include cancer immunotherapy, immune metabolism, mechano-immunology, and biomaterials. She investigates how physical and biochemical cues can reprogram T cells, overcome exhaustion, and enhance tumor targeting. Her work emphasizes multidimensional immunity-disease interactions, aiming to develop safer and more effective therapies for cancer and autoimmune diseases. The recent publications highlight a strong trend in engineering immune cells (especially CAR-T) for enhanced durability and function, using advanced biomaterials and metabolic reprogramming. There is a clear focus on overcoming challenges in solid tumors, modulating the tumor microenvironment, and translating findings into clinical applications. The use of nanoparticle delivery, single-cell analysis, and biomechanical cues are recurring themes across her work. Notable scientific awards include: Friedrich Miescher Award (2025) ERC Starting Grant (2018) MIT TR35 Innovators Under 35 (China Region, 2020) Nano Research Young Innovator Award (2018) Biomaterials Science Emerging Investigator (2019) Materials Horizons Emerging Investigator (2020) Li Tang actively mentors PhD students across multiple doctoral programs (EDBB, EDMS, EDMX) and has advised numerous graduates who have gone on to prestigious postdoctoral and faculty positions. She is involved in significant research grants, including an Innosuisse project with Novochizol SA, and her lab is supported by competitive funding. She teaches core courses such as Immunoengineering and Next-Generation Biomaterials, shaping the next generation of scientists. Her lab fosters interdisciplinary collaboration and innovation, with active projects in chemical, metabolic, and mechanical immunoengineering, as well as CAR-T cell development. She is the Principal Investigator of the Tang Lab, which includes postdoctoral fellows, PhD students, and technical staff. The lab is actively recruiting and has a strong publication and clinical translation record. Tang Lab is also involved in multiple MA/BA training projects and promotes student engagement in cutting-edge research. The lab’s discoveries are being translated into clinical trials, reflecting a strong commitment to translational science.

• Animal Nutrition
• Dairy Cattle
• Methane Emission
• +۲ مورد دیگر

Jan Dijkstra is an Associate Professor at Wageningen University specializing in Animal Nutrition . His research focuses on dairy cattle nutrition, methane emissions, and nutrient efficiency. Academic Rank: Associate Professor Department: Animal Nutrition His work emphasizes: Mathematical modelling of methane production Phosphorus and nitrogen balance optimization Feed supplementation strategies for reduced emissions Genotype-environment interactions in dairy systems Recent publications highlight advancements in methane mitigation , nutrient cycling , and rumen microbiome dynamics . He serves as a promotor for multiple PhD projects and contributes to datasets on equine microbiomes and rumen metabolites. Scientific Awards American Feed Industry Association Award (2015) Publicatieprijs ASG (2013) Supervision PhD candidates: Kozorezov, Henry, Koning, Vivares Martinez EngD candidate: Holshof

Adane Tilahun Getachewمشاهده پروفایل

دانشیار

• Antioxidant Research
• Bioactive Compounds
• Extraction Technologies
• +۳ مورد دیگر

Adane Tilahun Getachew serves as an Associate Professor at the National Food Institute, Technical University of Denmark (DTU), specializing in bioactive compounds analysis and application within food science. His research integrates green extraction technologies with sustainable food processing to valorize marine and agricultural byproducts. His primary research interests focus on antioxidant mechanisms , bioactive compound recovery , and advanced extraction methodologies including supercritical fluids and subcritical water processing. Key application areas include marine lipid extraction from invasive species like starfish and round goby, plant protein isolation from legumes and lupin seeds, and stabilization of omega-3 enriched food products. His work directly contributes to UN Sustainable Development Goals through waste reduction and sustainable resource utilization. Analysis of his 15 most recent publications reveals a strong emphasis on extraction optimization (particularly supercritical CO 2 and pressurized liquid methods), marine bioactives (seaweed, starfish, shrimp waste), and food product development (mayonnaise, packaging films, protein concentrates). Dominant themes include response surface methodology applications, seasonal variation impacts on bioactive yields, and techno-functional properties of extracted compounds. His collaborative projects demonstrate extensive interdisciplinary work across European research initiatives: SUSTAINABLE JET FUELS (2024-2027): Micro-algal cell factories for zero-waste aviation fuel GrExOmega (2022-2025): Green extraction of omega-3 from invasive marine species AlgaeVita (2025-2027): Biofortified algae ingredients rich in vitamin D3 and omega-3 SBbioact (2019-2022): Biorefinery of Nordic brown algae bioactives Dr. Getachew leads research on sustainable food systems with emphasis on waste valorization and green processing technologies, maintaining active collaborations with multiple European institutions through DTU's National Food Institute infrastructure.

Theresa Raimondoمشاهده پروفایل

استادیار

• Biomaterials
• Drug Delivery
• RNA-based Therapeutics
• +۵ مورد دیگر

Theresa Raimondo is the Manning Assistant Professor of Engineering at Brown University, with a secondary appointment in the Division of Biology and Medicine. She joined the Brown Engineering faculty in January 2024 after completing her postdoctoral training at MIT's Koch Institute. Dr. Raimondo leads the Raimondo Research Lab, which focuses on chemically modifying RNA and designing nanoparticles for therapeutic delivery to the body, an immunotherapy concept that holds immense promise in the field of immunoengineering. Her educational background includes: PhD in Engineering Sciences – Bioengineering from Harvard University (2019) MEng from Harvard University (2019) Sc.B. in Chemical and Biochemical Engineering from Brown University (2011) Dr. Raimondo's research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her work primarily centers on developing novel lipid nanoparticles (LNPs) for RNA-based therapies, contributing to adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By optimizing LNP formulation and modulating RNA constructs, she seeks to understand how RNA-LNPs modulate immunity and develop new therapeutic approaches. Her expertise spans biomaterials, drug delivery, biomolecular engineering, nanomedicine, tissue engineering, and regenerative medicine. Analysis of Dr. Raimondo's recent publications reveals a strong focus on RNA delivery systems and lipid nanoparticle technology. Her work spans from fundamental studies on nanoparticle design to applications in cancer immunotherapy, vaccine development, and tissue regeneration. A significant portion of her research involves optimizing lipid formulations for improved mRNA delivery and exploring how these systems interact with the immune system. Her publications demonstrate a trajectory from basic biomaterials research to increasingly translational work with therapeutic applications. Dr. Raimondo has received numerous prestigious awards: 2025 NAE Symposium selection (Grainger Foundation Frontiers of Engineering) 2025 appointment to the inaugural Early Career Board of ACS Applied Bio Materials 2024 selection as MIT Faculty Founder Initiative finalist 2022 Convergence Scholar fellowship from MIT's Marble Center for Cancer Nanomedicine National Science Foundation graduate research fellowship Harvard's Smith family graduate fellowship Dr. Raimondo is actively involved in mentoring students through courses including ENGN 0931L - Biomedical Engineering Design and Innovation II, ENGN 1490 - Biomaterials, and ENGN 1931L - Biomedical Engineering Design and Innovation II. Her research program is supported by various grants, though specific funding sources aren't detailed in the provided text. The Raimondo Research Lab represents a dynamic environment where engineering principles are applied to solve complex biological challenges in drug delivery and regenerative medicine. The Raimondo Research Lab at Brown University serves as a hub for innovation in RNA delivery and biomaterials design. The lab brings together expertise in chemical engineering, molecular biology, and immunology to develop next-generation therapeutic platforms. Current research directions include optimizing lipid nanoparticle formulations, exploring novel RNA modifications, and investigating immune responses to RNA therapeutics across various disease contexts.

Rajendra Kurapatiمشاهده پروفایل

استادیار

• Biodegradable Nanomaterials
• Nanomedicine
• Bioengineering
• +۵ مورد دیگر

Dr. Rajendra Kurapati is an Assistant Professor at the School of Chemistry , Indian Institute of Science Education and Research Thiruvananthapuram (IISER TVM) . His research focuses on biodegradable 2D materials for biomedical applications, addressing nanomaterial biopersistence issues through enzymatic degradation studies. He leads the Biomaterials Lab and collaborates with institutions across France, Ireland, Portugal, and the UK. Born in Andhra Pradesh, India B.Sc. & M.Sc. in Chemistry (Acharya Nagarjuna University, University of Hyderabad) Ph.D. in Materials Engineering (Indian Institute of Science, 2014) Postdoc: CNRS Strasbourg (2014-2017), CÚRAM Galway (2018-2020) His research explores 2D material-biopolymer hybrids for drug/gene delivery , nanotheranostics , and antimicrobial coatings . Key article trends include: Graphene/MoS2 biodegradation by human enzymes Antibacterial coatings for medical implants Microplastics' environmental impact Lipid nanoparticles for mRNA vaccines ZnO quantum dots for bioimaging Polymer multilayer drug delivery systems Major scientific awards : DBT Ramalingaswami Fellowship (INR 40 lakhs over 5 years) SERB Start-up Grant (32 lakhs over 2 years) SERB Special Grant (45 lakhs over 3 years) DBT Mission Innovation Grant (18 lakhs over 6 months) His academic contributions span 15+ high-impact publications in journals like Advanced Materials , Nanoscale , and Chemical Communications , covering topics from graphene biodegradation to antimicrobial coatings and bioimaging . 10+ alumni students have graduated from his lab, with placements at institutions including University of Strasbourg and Dublin City University.

Jessica Rosenholmمشاهده پروفایل

استاد

• Drug Delivery Systems
• Nanomedicine
• Biomaterials Engineering
• +۶ مورد دیگر

Jessica Rosenholm is a Professor at the Faculty of Science and Engineering, Department of Pharmacy at Åbo Akademi University. Her research focuses on drug delivery systems, nanomedicine, and biomaterials engineering. She holds a D.Sc.(Tech.) and has authored over 200 publications. Key research areas include mesoporous silica nanoparticles, 3D bioprinting, and antimicrobial resistance solutions. Her work contributes to UN Sustainable Development Goals, particularly in advancing health technologies. Notable achievements include the Akzo Nobel Nordic Research Prize 2009 and the Knight, First Class, of the Order of the White Rose of Finland (2022). She leads projects like the MADNESS Centre of Excellence, exploring materials-driven solutions against antimicrobial resistance. Education: Doctor of Science (Technology) Research Interests: Nanoformulations, biomedical imaging, microfluidics, and tissue engineering. Recent articles highlight innovations in programmable nanocomposites for hearing loss treatment, microfluidic assembly of nanostructures, and 3D printing of drug delivery systems. Awards: ÅAU Chancellor’s Prize (2013), Forskarpriset ur Harry Elvings legat (2009) Grants: Projects funded by EU, Finnish Research Council, and Sigrid Jusélius Foundation. Labs/Teams: BioNanoMaterials group explores cutting-edge technologies like nanomedical agents and microfluidics. Current projects include the NAP4DIVE initiative for blood-brain barrier drug delivery.

Cecilia Lealمشاهده پروفایل

استاد

• Soft Condensed Matter
• Biomaterials
• Drug Delivery
• +۵ مورد دیگر

Cecilia Leal is a Professor and Racheff Faculty Scholar in the Department of Materials Science and Engineering at the University of Illinois at Urbana-Champaign, with additional appointments at the Carle Illinois College of Medicine, Materials Research Laboratory, and Beckman Institute. Her interdisciplinary research program bridges materials science, biophysics, and medicine to develop innovative therapeutic delivery systems. Dr. Leal's research focuses on the self-organization of biomolecular systems, particularly lipid membranes, peptides, and nucleic acids. Her lab investigates how structural complexity of lipids and bio-membranes relates to disease mechanisms and informs the design of better gene and drug delivery systems. Key projects include developing lipid nanoparticles for mRNA delivery, studying polymer-lipid hybrid membranes, and characterizing lipid droplet dynamics in metabolic diseases. The lab employs advanced techniques including Small Angle X-ray Scattering, Cryo-EM, and live cell imaging. Her recent publications (2023-2025) reveal a strong emphasis on lipid-based delivery systems for mRNA therapeutics and cancer treatment, with particular attention to how nanostructure affects delivery efficiency. The research spans from fundamental biophysics of lipid-polymer interactions to applied therapeutic development, demonstrating consistent translation of basic science to medical applications. University of Illinois Provost's Distinguished Promotion to Full Professor Award (2024) University of Illinois Scholar (2023) NIH New Innovator Award (2016) NSF CAREER Award (2016) Racheff Faculty Scholar Award (2019) Dr. Leal has mentored numerous graduate students and postdocs, many now in prominent positions at MIT, Stanford, Dow Chemical, and pharmaceutical companies. Her research is supported by multiple NIH and NSF grants, and she maintains active collaborations with medical researchers studying obesity, cancer, and respiratory diseases. She teaches core courses including MSE 201 (Phases and Phase Relations) and MSE 473 (Biomolecular Materials Science), consistently earning excellent teaching ratings. The Leal Lab operates as an interdisciplinary team of materials scientists, physicists, and chemists using cutting-edge characterization tools to solve biomedical challenges. The lab's work on lipid nanoparticle structure has direct relevance to next-generation mRNA vaccines and cancer therapies, with several publications highlighted in C&EN News and other prominent scientific media.

• Drug Delivery
• Pharmaceutics
• Nanomedicine
• +۵ مورد دیگر

Caitriona M. O'Driscoll is Professor and Chair of Pharmaceutics at University College Cork's School of Pharmacy, Ireland. With over four decades of academic experience, she previously served as Head of the School of Pharmacy at UCC from 2003-2009 and 2010-2013. Her established drug delivery research team spans from pre-formulation through to production and manufacture of prototype delivery systems suitable for clinical trial, with strong industry links underpinning many research projects. Her research interests focus on translational drug delivery with emphasis on 'problem' drugs including poorly water soluble compounds and biopharmaceuticals like peptide/protein drugs, plasma DNA and siRNA. She develops nano-sized delivery constructs that are robust enough to survive processing, stable on storage, and achieve cell/site specific delivery in vivo. Greater than 40% of new chemical entities are poorly water soluble Biopharmaceuticals now approach 50% of all new drugs in development Major barrier is design of efficient delivery systems Special focus on oral drug delivery despite challenges Analysis of her recent publications reveals a strong emphasis on targeted nanodelivery systems for cancer therapy, particularly prostate and colorectal cancer, as well as neurodegenerative diseases like Huntington's. Her work demonstrates expertise in cyclodextrin-based nanoparticles, siRNA delivery, and disease-specific formulations that account for conditions like Crohn's disease that affect drug delivery. Scientific awards include: 'Person of the Year award' by Parenteral Drug Association (Ireland Chapter) in 2013 'Award for Professional Excellence' by Helix Health in 2007/2008 'Award for Pharmacist of the Year' by Helix Health in 2007/2008 With €10.5M in career research income and 25 PhDs graduated, Professor O'Driscoll's work has attracted funding from diverse sources including Science Foundation Ireland, Enterprise Ireland, and industry partners. Her research group maintains strong links with Pharmaceutical Chemistry and Process & Chemical Engineering at UCC, creating a unique strength for drug development research from design through to clinical trial. She has served as external examiner for multiple universities and as PhD thesis examiner at institutions worldwide. Her research team operates within UCC's drug delivery group, which has established expertise spanning from pre-formulation through to production and manufacture of prototype delivery systems. The group maintains strong industry connections and offers various PhD positions, focusing particularly on translational research with product-driven applications.

Kelsey Swingleمشاهده پروفایل

استادیار

• Biomaterials Science
• Immune Engineering
• Reproductive Biology
• +۶ مورد دیگر

Kelsey Swingle is an Assistant Professor of Bioengineering at Rice University, where she leads the Swingle Lab at the intersection of biomaterials science, immune engineering, and reproductive biology. Her research focuses on engineering therapeutic and vaccine technologies with translational potential. Ph.D. in Bioengineering from the University of Pennsylvania B.S.E. in Biomedical Engineering from Case Western Reserve University Dr. Swingle’s research explores the design of lipid nanoparticles (LNPs) and nucleic acid therapeutics for women’s health applications, including pre-eclampsia, preterm birth, and gynecologic cancers. Her work integrates bioengineering principles with immune modulation strategies to develop targeted therapies. The trends in her publications highlight advancements in LNP elasticity optimization for placental mRNA delivery, targeted systemic RNA delivery to the brain, and in utero gene editing applications. Her lab prioritizes interdisciplinary approaches to overcome biological barriers in women’s health. 2025 Solomon R. Pollack Award for Excellence in Graduate Bioengineering Research 2024 Muriel Joan Drew Hege Award for Women in Cellular Immunotherapy Research 2024 Penn Engineering Outstanding Teaching Award 2023 Gordon Research Conference Travel Award 2022 Society for Biomaterials STAR Award 2020 NSF Graduate Research Fellowship The Swingle Lab collaborates with the Texas Medical Center to develop precision nanomedicines. Her team employs in vitro, ex vivo, and in vivo models to study biomaterial interactions with female-specific tissues, emphasizing translational research and inclusive scientific communication.

Kuo-Ching Meiمشاهده پروفایل

استادیار

• mRNA therapeutics
• lipid nanoparticles (LNPs)
• RNA delivery
• +۷ مورد دیگر

Kuo-Ching Mei is an Assistant Professor of Molecular Pharmaceutics in the College of Pharmacy at the University of Utah. His laboratory pioneers lipid nanoparticle (LNP)-based gene delivery platforms that span cancer immunotherapy, immune tolerance induction, and programmable nanomedicine. Education B.Sc., Taipei Medical University Ph.D., University of London Dr. Mei’s research integrates molecular pharmaceutics, immunoengineering, and translational pharmaceutical sciences to advance precision immunotherapies. Core themes include mRNA-LNP systems for both immunostimulatory (anti-cancer vaccines) and immunomodulatory (tolerogenic) applications, the influence of immunometabolic cues (IFN-γ, amino-acid deprivation) on RNA translation, and the development of next-generation lipid chemistries for organ- and cell-specific delivery. Across his recent publications, a clear trend emerges toward refining LNP composition and architecture to enhance RNA delivery specificity, minimize toxicity, and modulate innate and adaptive immunity. Studies range from fundamental formulation science to pre-clinical evaluation in syngeneic tumor models and assessments of anti-vector immune responses. Research Support & Collaborations While specific grant numbers are not listed, the breadth and continuity of projects—from programmable lipid synthesis to high-throughput in vivo screening—indicate robust funding and active interdisciplinary collaborations within the University of Utah’s bioscience ecosystem. Laboratory & Team Dr. Mei leads a dynamic lab that employs chemical synthesis, formulation development, high-throughput screening, and integrated in vitro/in vivo disease models to translate discoveries into clinically viable RNA therapeutics and immunoengineering solutions.

Ravi Shuklaمشاهده پروفایل

استاد

• Nanobiotechnology
• Bioscience
• Medical Biotechnology
• +۶ مورد دیگر

Professor Ravi Shukla is a faculty member at RMIT University's School of Science, holding the title of Professor and Deputy Head of Department (Research). He specializes in Nanobiotechnology, with research spanning biomaterials, drug delivery systems, and medical diagnostics. His work integrates biosciences, materials science, and food technology to advance understanding of nanomaterial-biomolecular interactions. Academic History: Professor Shukla has held roles at RMIT since 2011, progressing from Research Fellow to his current professorship. He also serves as an Adjunct Professor at the University of Missouri and Theme Leader for Nanobiotechnology at RMIT’s Center for Advanced Materials and Industrial Chemistry. His teaching focuses on fostering student belonging and innovation in biotechnology education, including coordinating RMIT’s undergraduate Biotechnology program. Research Interests: His lab explores hybrid biomaterial synthesis, nano-enabled proteomics, and non-viral gene therapy using MOFs. Recent work emphasizes applications in diabetes biosensing, CRISPR/Cas9 delivery, and antimicrobial resistance mitigation through nanostrategies. Over 130+ publications and substantial research funding highlight his interdisciplinary impact. Professional Engagement: Editor roles in Frontiers in Bioengineering and Biotechnology , Co-Editor-in-Chief of Current Research in Nutrition and Food Science , and advisor to the Australasian Association of Ayurveda underscore his leadership. He actively mentors students in projects like nano-antimicrobial wound healing and aptamer-based hepatitis A detection. Key Achievements: Pioneered nucleic acid-encapsulated MOFs for cancer therapy and developed paper-based biosensors for rapid diagnostics. His work aligns with UN Sustainable Development Goals 2 (Zero Hunger) and 3 (Good Health).

Alexandra Piotrowski-Daspitمشاهده پروفایل

استادیار

• Gene Therapy
• Biomaterials
• Nanoparticle Delivery
• +۳ مورد دیگر

Dr. Alexandra Piotrowski-Daspit is an Assistant Professor in the Biomedical Engineering department and Internal Medicine – Pulmonary and Critical Care Medicine at the University of Michigan Medical School. She is a chemical/biological engineer with expertise in polymeric biomaterials for gene therapies, focusing on in vivo behavior of delivery vehicles and strategies to optimize biodistribution. Education: Ph.D. in Chemical/Biological Engineering Her research bridges polymer chemistry, gene delivery, and translational medicine, emphasizing in utero interventions and pulmonary targeting. Key areas include nanoparticle surface engineering, macrophage decoys, and computational pharmacokinetic modeling. Recent publications highlight systemic in utero gene editing for cystic fibrosis, poly(amine-co-ester) nanoparticle tunability, and mucosal vaccination platforms. She also explores miRNA therapies for congenital diaphragmatic hernia and triplex-forming PNAs for CFTR correction. PhRMA Foundation Awardee (2024) Her work involves interdisciplinary collaborations, DEI initiatives, and translational projects from postdoc foundations in W. Mark Saltzman’s lab. Labs like Saltzman and SCGE teams support her research.

• Pharmaceutical Technology
• Drug Delivery
• Nanoparticles
• +۴ مورد دیگر

Jouni Hirvonen is a Professor in the Division of Pharmaceutical Chemistry and Technology at the University of Helsinki's Faculty of Pharmacy. He serves as Supervisor for doctoral programmes in both the Doctoral Programme in Drug Research and the Doctoral Programme in Materials Research and Nanosciences. With an extensive publication record spanning over three decades, Hirvonen has contributed 384 research outputs and participated in 3 major research projects. His research interests focus on pharmaceutical technology, particularly in drug delivery systems, nanoparticles, and drug dissolution and absorption. His work bridges pharmaceutical chemistry with cutting-edge nanotechnology applications, developing innovative delivery systems for therapeutic agents. His research spans from fundamental pharmaceutical sciences to translational applications in regenerative medicine, immunotherapy, and cardiovascular pharmacology. The analysis of his recent publications reveals a strong focus on advanced drug delivery platforms, particularly utilizing nanoparticles, lipid-based systems, and biomaterials for targeted delivery. His work increasingly integrates microfluidic technology for precise nanoparticle preparation, with applications spanning cancer immunotherapy, cardiovascular repair, tendon regeneration, and inflammatory disease treatment. The trend shows a growing emphasis on combination therapies, RNA delivery, and cell-mediated drug delivery approaches. Hirvonen has received several prestigious awards throughout his career: CRS/Eurand Grand Prize Award on Innovations in Oral Drug Delivery Technologies (2007) Suomen Valkoisen Ruusun Ritarikunnan I luokan ritarimerkki (2013) The Young Scientist in the University of Kuopio (1993) University of Helsinki Quality Teaching Unit, Faculty of Pharmacy (2005) Visiting Professor award (2015) With 25 instances of supervising doctoral theses and numerous academic activities including conference organization, committee memberships, and editorial work, Hirvonen has made significant contributions to academic mentorship and institutional development. His research has been supported by projects including Generation Green, 3i REGENERATION, and IVIVRe. His work appears to involve collaboration with multiple research teams focusing on drug delivery applications across various therapeutic areas.

• Ophthalmology
• Retinal Degeneration
• Nanomedicine
• +۳ مورد دیگر

Dr. Ling Zhu is an Associate Professor and Senior Research Fellow at the Save Sight Institute, University of Sydney. He holds dual affiliations with the Centre for Drug Discovery Innovation and the University of Sydney Nano Institute. His research focuses on retinal diseases, including diabetic retinopathy, age-related macular degeneration, and macular telangiectasia type 2, combining clinical and basic research approaches. Dr. Zhu leads a lab with a postdoc, two research assistants, and one HDR student, emphasizing innovative techniques like human retinal explant culture and nanomedicine. Dr. Zhu obtained his PhD in Biochemistry from Rutgers University (USA) in 2008. His work has attracted over $2 million in research funding in the past five years and includes 93 publications (3590 citations, H-index 34). He is a major author in leading journals like eLife and Ophthalmology . Current research projects include preclinical RNA-LNP therapy for retinal degeneration, targeting retinal metabolism for macular diseases, and developing a 'Macula-on-a-Chip' drug screening platform. His expertise spans biochemistry, molecular biology, and translational nanomedicine. Key achievements include establishing human retinal explant models and advancing lipid nanoparticle-based drug delivery systems. Dr. Zhu collaborates widely, with projects addressing unmet clinical needs in ophthalmology and drug discovery.